



(51) International Patent Classification:

A61K 31/496 (2006.01) A61K 31/554 (2006.01)

A61K 31/50 (2006.01) A61K 45/06 (2006.01)

A61K 31/519 (2006.01) A61P 25/18 (2006.01)

(21) International Application Number:

PCT/US2022/018112

(22) International Filing Date:

28 February 2022 (28.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/200,327 01 March 2021 (01.03.2021) US

63/229,945 05 August 2021 (05.08.2021) US

63/264,747 01 December 2021 (01.12.2021) US

63/265,628 17 December 2021 (17.12.2021) US

(71) Applicants: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka, Osaka 540-8645 (JP). **NEUROCRINE BIOSCIENCES, INC.** [US/US]; 12780 El Camino Real, San Diego, California 92130 (US).

(72) Inventors: **PATHI JAGANNATHAM, Naga Venkatesha Murthy**; c/o Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139 (US). **HAREL, Brian**; c/o Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139 (US). **DEMARTINIS, Nicholas**; c/o Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139 (US). **DUNAYEVICH, Eduardo**; c/o Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139 (US). **O'DONNELL, Patricio**; c/o Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139 (US). **MACEK, Thomas A.**; c/o Takeda Development Center Americas, Inc., 95 Hayden Avenue, Lexington, Massachusetts 02421 (US). **BRAR, Satjit Singh**; c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US). **FUREY, Maura L.**; c/o Neurocrine Bio-

sciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US). **GE, Tingting**; c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US). **SINGH, Jaskaran B.**; c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US).

(74) Agent: **MACALPINE, Jill K.** et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: USE OF LUVADAXISTAT FOR THE TREATMENT OF COGNITIVE IMPAIRMENT



(57) Abstract: Methods of treating at least one cognitive symptom, e.g., at least one cognitive symptom associated with schizophrenia, comprising administering at least one compound chosen from Compound (I) and pharmaceutically acceptable salts thereof are disclosed. Also disclosed are methods of increasing D-serine levels, synaptic plasticity, and/or long-term potentiation comprising administering at least one compound chosen from Compound (I) and pharmaceutically acceptable salts thereof.

